Total Payments
$876,779
2024 Payments
$388,479
Companies
25
Transactions
790
Medicare Patients
6,746
Medicare Billing
$476,187
Payment Breakdown by Category
Other$477,172 (54.4%)
Consulting$311,996 (35.6%)
Travel$63,123 (7.2%)
Food & Beverage$21,128 (2.4%)
Research$2,926 (0.3%)
Education$434.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $475,300 | 112 | 54.2% |
| Consulting Fee | $311,996 | 107 | 35.6% |
| Travel and Lodging | $63,123 | 185 | 7.2% |
| Food and Beverage | $21,128 | 373 | 2.4% |
| Unspecified | $2,926 | 3 | 0.3% |
| Honoraria | $1,871 | 2 | 0.2% |
| Education | $434.31 | 8 | 0.0% |
Payments by Type
General
$873,853
787 transactions
Research
$2,926
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $234,269 | 138 | $0 (2024) |
| GENZYME CORPORATION | $150,072 | 96 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $125,955 | 152 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $93,240 | 47 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $88,186 | 87 | $0 (2024) |
| UCB, Inc. | $69,435 | 77 | $0 (2024) |
| Janssen Biotech, Inc. | $26,142 | 32 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $18,535 | 9 | $0 (2024) |
| PFIZER INC. | $14,264 | 15 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $13,167 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $388,479 | 273 | E.R. Squibb & Sons, L.L.C. ($109,482) |
| 2023 | $340,274 | 250 | E.R. Squibb & Sons, L.L.C. ($124,428) |
| 2022 | $53,466 | 72 | UCB, Inc. ($20,986) |
| 2021 | $27,498 | 21 | Novartis Pharmaceuticals Corporation ($10,552) |
| 2020 | $10,421 | 8 | LEO Pharma Inc. ($4,110) |
| 2019 | $20,193 | 39 | Novartis Pharmaceuticals Corporation ($15,532) |
| 2018 | $30,676 | 95 | PFIZER INC. ($9,633) |
| 2017 | $5,771 | 32 | Novartis Pharmaceuticals Corporation ($3,215) |
All Payment Transactions
790 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $199.14 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Immunology | ||||||
| 12/21/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $184.34 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $918.53 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $262.20 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $171.46 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $122.22 | General |
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,416.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,200.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,416.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,708.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,416.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,697.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $66.30 | General |
| Category: Immunology | ||||||
| 11/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,967.00 | General |
| Category: Immunology | ||||||
| 11/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,551.00 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Immunology | ||||||
| 11/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,326.95 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $1,641 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,285 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 14 | 2,548 | 4,085 | $1.0M | $173,534 |
| 2021 | 17 | 2,374 | 3,772 | $920,048 | $181,320 |
| 2020 | 14 | 1,824 | 2,619 | $610,842 | $121,333 |
Total Patients
6,746
Total Services
10,476
Medicare Billing
$476,187
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 479 | 593 | $203,887 | $36,991 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 283 | 336 | $163,440 | $28,733 | 17.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 485 | 552 | $174,096 | $23,757 | 13.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 308 | 308 | $129,640 | $22,302 | 17.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 122 | 141 | $92,055 | $17,337 | 18.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 194 | 201 | $79,596 | $13,721 | 17.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 150 | 159 | $69,668 | $11,879 | 17.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 364 | 1,624 | $46,219 | $7,430 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $34,352 | $5,864 | 17.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 24 | 25 | $12,030 | $2,259 | 18.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 21 | 28 | $5,656 | $978.63 | 17.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 28 | 28 | $5,995 | $922.11 | 15.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 24 | 24 | $6,963 | $782.76 | 11.2% |
| 11200 | Removal of skin tag, 1-15 skin tags | Office | 2022 | 11 | 11 | $3,728 | $578.71 | 15.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 309 | 386 | $165,833 | $36,574 | 22.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 384 | 472 | $139,476 | $30,709 | 22.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 341 | 341 | $137,113 | $26,944 | 19.7% |
| 17000 | Destruction of skin growth | Office | 2021 | 400 | 468 | $135,223 | $20,991 | 15.5% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 144 | 168 | $102,518 | $19,924 | 19.4% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 207 | 227 | $87,508 | $16,746 | 19.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 92 | 100 | $42,682 | $7,718 | 18.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 311 | 1,419 | $39,156 | $6,752 | 17.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $18,180 | $3,861 | 21.2% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 32 | 32 | $15,344 | $2,868 | 18.7% |
| 11602 | Removal of malignant growth (1.1 to 2.0 centimeters) of the trunk, arms, or legs | Office | 2021 | 11 | 11 | $10,265 | $2,099 | 20.4% |
About Jason Hawkes, MD, MS
Jason Hawkes, MD, MS is a Dermatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1356631873.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jason Hawkes, MD, MS has received a total of $876,779 in payments from pharmaceutical and medical device companies, with $388,479 received in 2024. These payments were reported across 790 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($475,300).
As a Medicare-enrolled provider, Hawkes has provided services to 6,746 Medicare beneficiaries, totaling 10,476 services with total Medicare billing of $476,187. Data is available for 3 years (2020–2022), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Portland, OR
- Active Since 04/18/2011
- Last Updated 08/02/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1356631873
Products in Payments
- DUPIXENT (Biological) $162,328
- SPEVIGO (Drug) $69,489
- Sotyktu (Drug) $50,307
- COSENTYX (Biological) $43,940
- Bimzelx (Biological) $37,085
- TREMFYA (Drug) $23,209
- VTAMA (Drug) $11,020
- DUPIXENT (Drug) $7,788
- COSENTYX (Drug) $6,487
- Zoryve (Drug) $5,107
- LIBTAYO (Biological) $4,749
- Tremfya (Drug) $4,608
- EUCRISA (Drug) $2,869
- ILUMYA (Biological) $2,815
- Humira (Biological) $1,887
- AYVAKIT (Drug) $1,863
- SILIQ (Drug) $930.29
- DUPIXENT DUPILUMAB INJECTION (Biological) $680.84
- TALTZ (Drug) $608.63
- STELARA (Biological) $406.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Portland
Andrew Blauvelt, Md, MD
Dermatology — Payments: $2.6M
Dermatology $2.6M
Eric Simpson, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Benjamin Ehst, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $1.5M
Dermatology $1.5M
Dr. Omar Qutub, Md, MD
Dermatology — Payments: $73,858
Dermatology $73,858
Alex Ortega Loayza, Md, MD
Dermatology — Payments: $72,824
Dermatology $72,824
Jon Hanifin, Md, MD
Dermatology — Payments: $66,868
Dermatology $66,868